Results 71 to 80 of about 4,520 (170)

Paxlovid in Kidney Failure: A Review

MPI (Media Pharmaceutica Indonesiana)
The COVID-19 virus caused a global pandemic that claimed many lives. Various vaccines and drugs are used for COVID-19 both via intravenous and oral routes. Paxlovid is a treatment given orally to patients who experience symptoms and is even considered effective in reducing high-risk COVID-19 virus infections.
Nonie Ardianty, null Suharjono, Didik Hasmono   +2 more
openaire   +1 more source

Peace, love, Paxlovid and ‘Pfizermectin’

, 2021
As the new Omicron variant of concern of COVID-19 emerged over Thanksgiving week (of all times!), attention has been turning to Paxlovid (PF-07321332). If, like me, you torment yourself by perusing conspiracy theories, you might have heard it referred to as Pfizermectin.
openaire   +1 more source

The path to Paxlovid

C&EN Global Enterprise, 2022
openaire   +2 more sources

Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China

Infection and Drug Resistance
Wei Yang,1,* Yahui Peng,1,* Changsong Wang,1,* Hongliu Cai,2 Lina Zhang,3 Jun Xu,2 Yongjie Wang,4 Maonan Wang,4 Mingyan Zhao,1 Kaijiang Yu1 1Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University ...
Yang W, Peng Y, Wang C, Cai H, Zhang L, Xu J, Wang Y, Wang M, Zhao M, Yu K   +9 more
doaj  

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +1 more source

Yi-Qing Oral Solution and Paxlovid combination for COVID-19: Efficacy and safety in a randomized controlled trial

Traditional Medicine and Modern Medicine
Background: The COVID-19 pandemic has exerted a significant social burden worldwide. Traditional Chinese medicine has emerged as a vital role in the clinical management of COVID-19.
Maimaititusun Yalikun, Xi Huang, Xueyi Zhu, Yuxue Cao, Jiming Zhang, Xin Ma, Jindong Hua, Jiaqi Liu, Xianjun Sun, Wenjing Du, Lingwen Kong, YanBo Ren, Hongli Xue, Baojun Liu, Yuanhao Zhang, Yang Lei, Zhen Gao, Weiyi Gong, Jingcheng Dong   +18 more
doaj   +1 more source

Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients

Scientific Reports
This retrospective cross-sectional study aims to evaluate the safety, tolerability, and adherence of patients prescribed Nirmatrelvir-ritonavir (Paxlovid) in outpatient settings, focusing on its use in managing category 2 COVID-19 patients across three ...
Zahirah Zaharuddin, Nur Sabiha Md Hussin, Mahmathi Karuppannan   +2 more
doaj   +1 more source

A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

eLife
Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients.
Zhanwei Du, Lin Wang, Yuan Bai, Yunhu Liu, Eric HY Lau, Alison P Galvani, Robert M Krug, Benjamin John Cowling, Lauren A Meyers   +8 more
doaj   +1 more source

Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis

Journal of Infection in Developing Countries
Introduction: Paxlovid (nirmatrelvir/ritonavir) is a new oral antiviral drug that is used for coronavirus disease 2019 (COVID-19) and is administered to patients with mild to moderate disease for five consecutive days.
Yu Wang, Yuya Yang, Rong Shan, Liangfeng Zhao, Yanyan Bai, Liuliu Feng   +5 more
doaj   +1 more source

Pandora’s box: Paxlovid, prescribing, pharmacists and pandemic [PDF]

Journal of Pharmacy Practice and Research, 2022
Roberts, Jason A., Duncan, Alison, Cairns, Kelly A.   +2 more
openaire   +4 more sources